American Society of Hematology

Fig. 4.

$Fig. 4. Reduced frequencies of EBV-specific cells in GMCs, as assessed by tetramer staining. / (A) Representative FACS profile of PBMCs, Co cells, and GMCs (donor no. 2) after staining with a PE-labeled HLA-A2/GLC tetramer complex and PC5-CD8 mAb. The fraction of tetramer+ cells (upper right quadrant) within the CD8+ cells (upper and lower right quadrants) are indicated above each dot plot. PBMCs, Co cells, and GMCs generated from donor no. 8 (HLA-A2+, EBV-seronegative) were used to set up the positivity level (not shown). Similar profiles were obtained with 3 additional HLA-A2+ EBV-seropositive donors. (B) Kinetics of tetramer staining during cell culture. PBMCs activated by CD3/IL-2 were cultured in the presence of IL-2 until day 12. Data are from 1 of 4 representative experiments.$

Reduced frequencies of EBV-specific cells in GMCs, as assessed by tetramer staining.

(A) Representative FACS profile of PBMCs, Co cells, and GMCs (donor no. 2) after staining with a PE-labeled HLA-A2/GLC tetramer complex and PC5-CD8 mAb. The fraction of tetramer⁺ cells (upper right quadrant) within the CD8⁺ cells (upper and lower right quadrants) are indicated above each dot plot. PBMCs, Co cells, and GMCs generated from donor no. 8 (HLA-A2⁺, EBV-seronegative) were used to set up the positivity level (not shown). Similar profiles were obtained with 3 additional HLA-A2⁺ EBV-seropositive donors. (B) Kinetics of tetramer staining during cell culture. PBMCs activated by CD3/IL-2 were cultured in the presence of IL-2 until day 12. Data are from 1 of 4 representative experiments.

This Feature Is Available To Subscribers Only